These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 28377241)

  • 1. Genetic epidemiological study doesn't support GLA IVS4+919G>A variant is a significant mutation in Fabry disease.
    Chiang HL; Wang NH; Song IW; Chang CP; Wen MS; Chien YH; Hwu WL; Tsai FJ; Chen YT; Wu JY
    Mol Genet Metab; 2017 May; 121(1):22-27. PubMed ID: 28377241
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fabry disease: incidence of the common later-onset α-galactosidase A IVS4+919G→A mutation in Taiwanese newborns--superiority of DNA-based to enzyme-based newborn screening for common mutations.
    Chien YH; Lee NC; Chiang SC; Desnick RJ; Hwu WL
    Mol Med; 2012 Jul; 18(1):780-4. PubMed ID: 22437327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation the alternative splicing of GLA (IVS4+919G>A) in Fabry disease.
    Chang WH; Niu DM; Lu CY; Lin SY; Liu TC; Chang JG
    PLoS One; 2017; 12(4):e0175929. PubMed ID: 28430823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Newborn screening for Fabry disease in Taiwan reveals a high incidence of the later-onset GLA mutation c.936+919G>A (IVS4+919G>A).
    Hwu WL; Chien YH; Lee NC; Chiang SC; Dobrovolny R; Huang AC; Yeh HY; Chao MC; Lin SJ; Kitagawa T; Desnick RJ; Hsu LW
    Hum Mutat; 2009 Oct; 30(10):1397-405. PubMed ID: 19621417
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Fabry disease-causing mutation, GLA IVS4+919G>A, originated in Mainland China more than 800 years ago.
    Liang KH; Lu YH; Niu CW; Chang SK; Chen YR; Cheng CY; Hsu TR; Yang CF; Nakamura K; Niu DM
    J Hum Genet; 2020 Jul; 65(7):619-625. PubMed ID: 32246049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma globotriaosylsphingosine (lysoGb3) could be a biomarker for Fabry disease with a Chinese hotspot late-onset mutation (IVS4+919G>A).
    Liao HC; Huang YH; Chen YJ; Kao SM; Lin HY; Huang CK; Liu HC; Hsu TR; Lin SP; Yang CF; Fann CS; Chiu PC; Hsieh KS; Fu YC; Ke YY; Lin CY; Tsai FJ; Wang CH; Chao MC; Yu WC; Chiang CC; Niu DM
    Clin Chim Acta; 2013 Nov; 426():114-20. PubMed ID: 24055776
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the diagnostic dilemma: A comprehensive review of the Taiwanese cardiac variant in Fabry disease.
    Hwu WL
    J Formos Med Assoc; 2024 Jul; 123(7):738-743. PubMed ID: 37833114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Genotype-phenotype analysis of Fabry disease caused by GLA gene variation in a pedigree].
    Ge ZH; Lu ZH; Pan XD; Lai TT; Yang MJ; Yang HQ; Zhang HB; Li GY; Dai ZQ; Mao JH
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):345-350. PubMed ID: 38527505
    [No Abstract]   [Full Text] [Related]  

  • 9. Enzyme assay and clinical assessment in subjects with a Chinese hotspot late-onset Fabry mutation (IVS4 + 919G→A).
    Lin HY; Huang CH; Yu HC; Chong KW; Hsu JH; Lee PC; Cheng KH; Chiang CC; Ho HJ; Lin SP; Chen SJ; Lin PK; Niu DM
    J Inherit Metab Dis; 2010 Oct; 33(5):619-24. PubMed ID: 20821055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation.
    Lee HJ; Hung SC; Hsu TR; Ko SC; Chui-Mei T; Huang CC; Niu DM; Lin CP
    AJNR Am J Neuroradiol; 2016 Jun; 37(6):1044-9. PubMed ID: 26869469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A).
    Liu HC; Lin HY; Yang CF; Liao HC; Hsu TR; Lo CW; Chang FP; Huang CK; Lu YH; Lin SP; Yu WC; Niu DM
    Orphanet J Rare Dis; 2014 Jul; 9():111. PubMed ID: 25047006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of central nervous system involvement in patients with classical Fabry disease or the later-onset subtype with the IVS4+919G>A mutation.
    Lee HJ; Hsu TR; Hung SC; Yu WC; Chu TH; Yang CF; Bizjajeva S; Tiu CM; Niu DM
    BMC Neurol; 2017 Feb; 17(1):25. PubMed ID: 28166746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lyso-globotriaosylsphingosine (lyso-Gb3) levels in neonates and adults with the Fabry disease later-onset GLA IVS4+919G>A mutation.
    Chien YH; Bodamer OA; Chiang SC; Mascher H; Hung C; Hwu WL
    J Inherit Metab Dis; 2013 Sep; 36(5):881-5. PubMed ID: 23109060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and functional characterization of the first deep intronic GLA mutation (IVS4+1326C>T) causing renal variant of Fabry disease.
    Dai X; Zong X; Pan X; Lu W; Jiang GR; Lin F
    Orphanet J Rare Dis; 2022 Jun; 17(1):237. PubMed ID: 35725559
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and mutation spectrum of GLA in Korean patients with Fabry disease by a nationwide survey: Underdiagnosis of late-onset phenotype.
    Choi JH; Lee BH; Heo SH; Kim GH; Kim YM; Kim DS; Ko JM; Sohn YB; Hong YH; Lee DH; Kook H; Lim HH; Kim KH; Kim WS; Hong GR; Kim SH; Park SH; Kim CD; Kim SM; Seo JS; Yoo HW
    Medicine (Baltimore); 2017 Jul; 96(29):e7387. PubMed ID: 28723748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alternative splicing in the alpha-galactosidase A gene: increased exon inclusion results in the Fabry cardiac phenotype.
    Ishii S; Nakao S; Minamikawa-Tachino R; Desnick RJ; Fan JQ
    Am J Hum Genet; 2002 Apr; 70(4):994-1002. PubMed ID: 11828341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High incidence of the cardiac variant of Fabry disease revealed by newborn screening in the Taiwan Chinese population.
    Lin HY; Chong KW; Hsu JH; Yu HC; Shih CC; Huang CH; Lin SJ; Chen CH; Chiang CC; Ho HJ; Lee PC; Kao CH; Cheng KH; Hsueh C; Niu DM
    Circ Cardiovasc Genet; 2009 Oct; 2(5):450-6. PubMed ID: 20031620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endomyocardial biopsies in patients with left ventricular hypertrophy and a common Chinese later-onset Fabry mutation (IVS4 + 919G > A).
    Hsu TR; Sung SH; Chang FP; Yang CF; Liu HC; Lin HY; Huang CK; Gao HJ; Huang YH; Liao HC; Lee PC; Yang AH; Chiang CC; Lin CY; Yu WC; Niu DM
    Orphanet J Rare Dis; 2014 Jul; 9():96. PubMed ID: 24980630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interleukin-18 deteriorates Fabry cardiomyopathy and contributes to the development of left ventricular hypertrophy in Fabry patients with GLA IVS4+919 G>A mutation.
    Chien Y; Chien CS; Chiang HC; Huang WL; Chou SJ; Chang WC; Chang YL; Leu HB; Chen KH; Wang KL; Lai YH; Liu YY; Lu KH; Li HY; Sung YJ; Jong YJ; Chen YJ; Chen CH; Yu WC
    Oncotarget; 2016 Dec; 7(52):87161-87179. PubMed ID: 27888626
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.